| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/22/2003 | EP1276729A1 New neurokinin antagonists for use as medicaments |
| 01/22/2003 | EP1276726A2 Substituted phenyl farnesyltransferase inhibitors |
| 01/22/2003 | EP1276725A2 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276724A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276722A1 Naphthamidine urokinase inhibitors |
| 01/22/2003 | EP1276720A2 2-acyl indol derivatives and their use as anti-tumour agents |
| 01/22/2003 | EP1276718A2 Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
| 01/22/2003 | EP1276713A1 Inhibition of angiogenesis and tumor growth |
| 01/22/2003 | EP1276504A2 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent |
| 01/22/2003 | EP1276501A2 Method for treatment of tumors using photodynamic therapy |
| 01/22/2003 | EP1276496A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 01/22/2003 | EP1276493A2 Cxcr4 agonist treatment of hematopoietic cells |
| 01/22/2003 | EP1276491A1 Tamandarin and didemnin analogs and methods of making and using them |
| 01/22/2003 | EP1276489A1 Novel medicines based on sesquiterpene mixtures |
| 01/22/2003 | EP1276484A2 Medicine containing polysaccharide substances for activating apoptosis |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276482A2 Combination chemotherapy |
| 01/22/2003 | EP1276468A1 Use of particulate vectors in immunomodulation |
| 01/22/2003 | EP1222459A4 Crystallographic structure of the androgen receptor ligand binding domain |
| 01/22/2003 | EP1165537B1 Hydroxymatairesinol in cancer prevention |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP0968213B1 Alkynyl-substituted camptothecins and process for their preparation |
| 01/22/2003 | EP0898562B1 Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
| 01/22/2003 | EP0865339B1 Metalloproteinase inhibitors |
| 01/22/2003 | EP0728009B1 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier |
| 01/22/2003 | CN1392876A Combretastatin A-4 phosphate prodrug, mono-and di-organic amine salt, mono-and di-amino acids salts, and mono-and di-amino acid ester salt |
| 01/22/2003 | CN1392796A Polyhydroxylated benzene-containing compounds |
| 01/22/2003 | CN1391952A Medicine for curing pain syndrome of late cancer and its preparation |
| 01/22/2003 | CN1391949A Chinese medicine compound preparation for curing pancreatic cancer |
| 01/22/2003 | CN1391942A New medicine for anti-cancer, anti-AIDs and giving-up drug habits and its preparing and applying method |
| 01/22/2003 | CN1391941A Capsule for curing tumor and its preparing method |
| 01/22/2003 | CN1391937A Oral liquor for curing tumor |
| 01/22/2003 | CN1391934A Chinese medicine prepn for expelling toxin and resisting cancer and its preparing method and use |
| 01/22/2003 | CN1391901A Injection for curing hemangioma |
| 01/22/2003 | CN1391892A Total gambogic acid preparation and its preparing method |
| 01/22/2003 | CN1391891A Taxol hidden liposome |
| 01/22/2003 | CN1391889A Tanshinone nano preparation and its preparing method |
| 01/22/2003 | CN1099296C Compositions including calcium influx retardant for inhibiting cell growth |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509370 Paclitaxel formulation |
| 01/21/2003 | US6509368 Use of catechol derivatives as proteinase inhibitors |
| 01/21/2003 | US6509365 Useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs. |
| 01/21/2003 | US6509363 P38 is a mitogen-activated protein kinase; pyrrole, oxazole, thiazole, and imidazole derivatives |
| 01/21/2003 | US6509356 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509345 For therapy of cancerous diseases |
| 01/21/2003 | US6509344 Indenoisoquinolines as antineoplastic agents |
| 01/21/2003 | US6509341 The invention relates to carboxylic acid derivatives of formula (I), wherein the substituents have the meaning as commented in the description. It also relates to the production and use of same as endothelin receptor antagonists. |
| 01/21/2003 | US6509334 Cyclocarbamate derivatives as progesterone receptor modulators |
| 01/21/2003 | US6509321 Treatment of Kaposi's sarcoma with IL-12 |
| 01/21/2003 | US6509318 TGF-B inhibitors and methods |
| 01/21/2003 | US6509313 Stimulation of immune response with low doses of cytokines |
| 01/21/2003 | US6509173 Related members of a broad class of polypeptide mediators, which includes the interferons, interleukins and growth factors, collectively called cytokines |
| 01/21/2003 | US6509162 Methods for selectively modulating survivin apoptosis pathways |
| 01/21/2003 | US6509155 Characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly colon cancer |
| 01/21/2003 | US6509016 Delaying recurrence of ganglioside 2 associated tumors; antibody comprising the light and heavy chain variable region sequences contained in seq id no: 2 and 4 |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6509001 Calcitonin receptor binding reagents |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/21/2003 | CA2098720C Cellular composition for the treatment of human or animal organisms |
| 01/21/2003 | CA2026690C Pleuromutilins |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/16/2003 | WO2003005493A1 Apparatus for a quick release safety connector assembly |
| 01/16/2003 | WO2003005036A2 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | WO2003004631A2 USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004613A2 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004527A2 Novel neurotrophic factors |
| 01/16/2003 | WO2003004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004507A1 A kind of oligosaccharides, their sulfates and dendrimers, and the uses of these compounds |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004488A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 01/16/2003 | WO2003004479A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | WO2003004473A1 Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| 01/16/2003 | WO2003004469A1 Anticancer activity of imino acid conjugates of methylglyoxal |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004466A2 Dye-sulfenates for dual phototherapy |
| 01/16/2003 | WO2003004454A1 Linked cyclitols and their polysulfated derivatives |
| 01/16/2003 | WO2003004091A2 Aromatic sulfenates for type i phototherapy |
| 01/16/2003 | WO2003004064A2 Products for treating ovarian cancers and for preventing relapses |
| 01/16/2003 | WO2003004063A1 Genetically engineered therapy method for treating gnrh receptor-positive carcinoma by gnrh-induced tumor cell-specific activation of a therapeutic gene, corresponding nucleic acid constructs and vectors |
| 01/16/2003 | WO2003004056A1 Method for treating multiple myeloma |
| 01/16/2003 | WO2003004049A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 01/16/2003 | WO2003004047A1 Cell death inducers for mast cells |
| 01/16/2003 | WO2003004046A2 Use of xaa-pro peptidases for the treatment of substance p-related disorders |
| 01/16/2003 | WO2003004041A1 Therapeutic composition including saw palmetto for cancer treatment |
| 01/16/2003 | WO2003004037A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | WO2003004023A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives |
| 01/16/2003 | WO2003004016A1 Use of substituted gamma-lactone compounds as medicaments |
| 01/16/2003 | WO2003004014A1 Organometallic anti-tumour agent |
| 01/16/2003 | WO2003004010A1 Carbonylamino derivatives useful for obtaining immune regulation |
| 01/16/2003 | WO2003004006A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | WO2003003985A2 Polyvalent conjugate vaccine for cancer |